These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. Schillaci O; DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; O'Donnell RT; Lamborn KR Cancer Biother Radiopharm; 2007 Aug; 22(4):521-30. PubMed ID: 17803447 [TBL] [Abstract][Full Text] [Related]
27. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Novak-Hofer I; Schubiger PA Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):821-30. PubMed ID: 12029558 [TBL] [Abstract][Full Text] [Related]
28. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Kukis DL; Diril H; Greiner DP; DeNardo SJ; DeNardo GL; Salako QA; Meares CF Cancer; 1994 Feb; 73(3 Suppl):779-86. PubMed ID: 8306260 [TBL] [Abstract][Full Text] [Related]
29. Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors. Delaloye AB; Delaloye B; Buchegger F; Vogel CA; Gillet M; Mach JP; Smith A; Schubiger PA J Nucl Med; 1997 Jun; 38(6):847-53. PubMed ID: 9189128 [TBL] [Abstract][Full Text] [Related]
30. Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody. Shen S; DeNardo GL; Yuan A; Hartmann-Siantar C; O'Donnell RT; DeNardo SJ Cancer Biother Radiopharm; 2005 Dec; 20(6):662-70. PubMed ID: 16398618 [TBL] [Abstract][Full Text] [Related]
31. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219 [TBL] [Abstract][Full Text] [Related]
32. Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model. DeNardo GL; DeNardo SJ; Macey DJ; Shen S; Kroger LA Cancer; 1994 Feb; 73(3 Suppl):1038-48. PubMed ID: 8306246 [TBL] [Abstract][Full Text] [Related]
33. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. DeNardo GL; DeNardo SJ; Lamborn KR; Goldstein DS; Levy NB; Lewis JP; O'Grady LF; Raventos A; Kroger LA; Macey DJ; McGahan JP; Mills SL; Shen S Cancer Biother Radiopharm; 1998 Aug; 13(4):239-54. PubMed ID: 10850360 [TBL] [Abstract][Full Text] [Related]
34. A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy. Shen S; DeNardo GL; Jones TD; Wilder RB; O'Donnell RT; DeNardo SJ J Nucl Med; 1998 Jul; 39(7):1223-9. PubMed ID: 9669399 [TBL] [Abstract][Full Text] [Related]
35. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. Scheinberg DA; Straus DJ; Yeh SD; Divgi C; Garin-Chesa P; Graham M; Pentlow K; Coit D; Oettgen HF; Old LJ J Clin Oncol; 1990 May; 8(5):792-803. PubMed ID: 2332769 [TBL] [Abstract][Full Text] [Related]
36. Strategies for enhancement of radioimmunotherapy. DeNardo G; DeNardo S; Kukis D; Diril H; Suey C; Meares C Int J Rad Appl Instrum B; 1991; 18(6):633-40. PubMed ID: 1743986 [TBL] [Abstract][Full Text] [Related]
38. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake. Juweid M; Sharkey RM; Siegel JA; Behr T; Goldenberg DM Cancer Res; 1995 Dec; 55(23 Suppl):5827s-5831s. PubMed ID: 7493354 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378 [TBL] [Abstract][Full Text] [Related]
40. A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy. Siegel JA; Kroll S; Regan D; Kaminski MS; Wahl RL J Nucl Med; 2002 Mar; 43(3):354-63. PubMed ID: 11884495 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]